VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced its plans for a Phase 2 clinical study evaluating VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine candidate, following positive discussions with Health...
Read More
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501 Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PT VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company,...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SABs) consisting of leading experts in infectious disease and immuno-oncology research and vaccine...
Read More
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest dose Safe and well-tolerated at all doses with no safety signals observed Conference call and webcast today, Thursday, May 10, 2018, at 8:30 AM...
Read More
Presentation to feature overview of positive interim Phase 1 CMV vaccine data and preclinical Zika vaccine data demonstrating neutralizing antibody response VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI) today announced that Adam Buckley, vice president of business development, will...
Read More
Well tolerated at all doses with no safety signals 100% seroconversion at highest dose after two of the three planned vaccinations Dose-dependent antibody responses against CMV gB antigen Full data after third dose expected first half of 2018 Conference Call...
Read More
Cytomegalovirus (“CMV”), a common virus that infects over half of adults by age 40, may cause changes in normal-weight women that could increase the risk of metabolic syndrome says new research led by investigators at the University of California, San Francisco...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today provided an update on its cytomegalovirus (“CMV”) Phase I clinical study, which is assessing the safety and tolerability of VBI’s vaccine candidate to prevent congenital CMV infection. Congenital CMV infection is...
Read More
Cytomegalovirus (“CMV”) is a common virus that infects one in every two people in many developed countries. Most CMV infections are “silent,” meaning most people who are infected with CMV exhibit no signs or symptoms. However, CMV can cause serious...
Read More